Consistently, a tendency for decreased levels of C4BPα in AD group (1.79 ± 0.75) when compared with Controls (1.72 ± 0.64) was likewise observed for the UMG-cohort (Fig. 8c). Here, C4BPA is linked to Alzheimer disease.